H. Lubenau

Pharmacokinetic and Pharmacodynamic Profile of New Biosimilar Filgrastim XM02 Equivalent to Marketed Filgrastim Neupogen®

H. Lubenau, P. Bias, A. Mały, 2012, BioDrugs.

XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

S. Paulo., A. Giglio, A. Eniu, 2008, BMC Cancer.

XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

U. Gatzemeier, T. Ciuleanu, M. Dediu, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial

W. Haefeli, J. Weitz, Y. Ge, 2015, Oncoimmunology.

Incidence of Febrile Neutropenia and Myelotoxicity of Chemotherapy: A Meta-Analysis of Biosimilar G-CSF Studies in Breast Cancer, Lung Cancer, and Non-Hodgkin’s Lymphoma

U. Gatzemeier, D. Heigener, A. Engert, 2009, Oncology Research and Treatment.

XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy

A. Giglio, L. Griškevičius, A. Engert, 2009, Leukemia & lymphoma.

A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer

M. Büchler, W. Haefeli, K. Breiner, 2017, Oncoimmunology.

Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers.

J. Macijauskiene, H. Lubenau, S. Kazlauskas, 2009, International journal of clinical pharmacology and therapeutics.

Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer

M. Koch, W. Haefeli, J. Weitz, 2012, BMC Cancer.

Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer

M. Koch, W. Haefeli, J. Weitz, 2012, BMC Cancer.

ATIM-35. VXM01 PHASE I STUDY IN PATIENTS WITH PROGRESSIVE GLIOBLASTOMA – FINAL RESULTS

A. Unterberg, A. von Deimling, C. Jungk, 2018, Neuro-Oncology.